Biomea Fusion

BMEA

Market cap $77.1M

SAN CARLOS, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in the upcoming investor conferences:

SAN CARLOS, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it is scheduled to participate in a fireside chat at the upcoming Jefferies London Healthcare Conference on November 17, 2025 at 4:30 PM (GMT) and will participate in one-on-one meetings on November 17-18, 2025 in London, UK.

SAN CARLOS, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the presentation of two late breaking posters at ObesityWeek® 2025 in Atlanta, Georgia.

Advances diabetes and obesity programs with icovamenib demonstrating durable 52-Week Phase II data and with BMF-650, Biomea's next-generation, oral small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), dosing its first patient in a Phase I clinical trial Presented preclinical activity of icovamenib in combination with semaglutide in type 2 diabetes (“T2D”) animal model at EASD Annual Meeting, demonstrating enhanced glycemic control and body weight reduction with preservation of lean mass Raised approximately $68 million in gross proceeds through two public offerings, extending projected cash runway into the first quarter of 2027 SAN CARLOS, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the third quarter ended September 30, 2025, and provided a business update.

SAN CARLOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will present poster presentations at ObesityWeek® 2025, taking place November 4-7, 2025 in Atlanta, Georgia.

SAN CARLOS, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that the first patient has been dosed in a Phase I clinical trial of BMF-650, the Company's investigational, next-generation oral small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”).

Biomea Fusion, Inc. (NASDAQ:BMEA ) Citi's 2025 SMID Cap Biopharma Call Series October 23, 2025 11:00 AM EDT Company Participants Ramses Erdtmann - Co-Founder, President, COO & Director Thorsten Kirschberg - Executive Vice President of Chemistry Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Citigroup Inc., Research Division All right. Hi, everyone.

SAN CARLOS, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in Citi's SMID Biotech C-Suite Fireside Chat Series on Thursday, October 23, 2025, at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time.

Biomea Fusion, Inc. - Special Call Company Participants Ramses Erdtmann - Co-Founder, President, COO & Director Michael J. Hitchcock - Interim CEO & Director Stephan Morris - Chief Development Officer Conference Call Participants Matthew Biegler - Oppenheimer & Co. Inc., Research Division Joseph Pantginis - H.C.

Biomea Fusion Inc‘s (NASDAQ:BMEA) stock price plummeted after the company priced its public offering.